Genelux Corp
GNLX
Company Profile
Business description
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Contact
2625 Townsgate Road
Suite 230
Westlake VillageCA91361
USAT: +1 805 267-9889
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
24
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,424.20 | 24.40 | 0.29% |
| CAC 40 | 7,626.84 | 70.08 | -0.91% |
| DAX 40 | 23,115.96 | 133.69 | -0.58% |
| Dow JONES (US) | 41,113.97 | 284.97 | 0.70% |
| FTSE 100 | 8,559.33 | 38.09 | -0.44% |
| HKSE | 22,949.32 | 257.44 | 1.13% |
| NASDAQ | 17,738.16 | 48.50 | 0.27% |
| Nikkei 225 | 36,863.15 | 83.49 | 0.23% |
| NZX 50 Index | 12,507.45 | 10.56 | 0.08% |
| S&P 500 | 5,631.28 | 24.37 | 0.43% |
| S&P/ASX 200 | 8,194.80 | 16.50 | 0.20% |
| SSE Composite Index | 3,354.01 | 11.34 | 0.34% |